Treatment for Healthy Subjects (HS)

Phase-Based Progress Estimates
Healthy Subjects (HS)
18 - 65
All Sexes
What conditions do you have?

Study Summary

This trial is testing whether a new drug is safe and tolerated when given to healthy subjects.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Healthy Subjects (HS)

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 60 Days

60 Days
Evaluate (PK) of STP707 when administered by IV in healthy subjects
60 days
Evaluate safety & tolerability of STP707 when administered by IV in healthy subjects

Trial Safety

Safety Progress

1 of 3

Other trials for Healthy Subjects (HS)

Trial Design

0 Treatment Group

50 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · Phase 1

Trial Logistics


Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 60 days

Who is running the clinical trial?

SirnaomicsLead Sponsor
10 Previous Clinical Trials
405 Total Patients Enrolled
Medpace, Inc.Industry Sponsor
87 Previous Clinical Trials
28,421 Total Patients Enrolled
5 Trials studying Healthy Subjects (HS)
530 Patients Enrolled for Healthy Subjects (HS)

Eligibility Criteria

Age 18 - 65 · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are 18 to 55 years of age, inclusive, at the time of signing the informed consent form.
You must be using a condom plus diaphragm.\n
Use a condom plus a cervical cap or female condom.
Use of barrier contraception methods by a partner is recommended.
Subjects must be in generally reasonable health with clinically insignificant screening and admission results (medical history, 12-lead electrocardiogram [ECG], physical examination, and laboratory tests), as determined by the Investigator.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 5th, 2021

Last Reviewed: October 3rd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.